(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) rose by a staggering 15.28% in 5 sessions from $3.86 at 15.28, to $4.45 at 14:43 EST on Monday, following the last session’s upward trend. NASDAQ is rising 0.17% to $13,262.87, after two successive sessions in a row of gains.
TherapeuticsMD’s last close was $4.40, 62.36% below its 52-week high of $11.69.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $2.07.
PE Ratio
TherapeuticsMD has a trailing twelve months price to earnings ratio of 2.15. Meaning, the purchaser of the share is investing $2.15 for every dollar of annual earnings.
Yearly Top and Bottom Value
TherapeuticsMD’s stock is valued at $4.45 at 14:43 EST, way under its 52-week high of $11.69 and way higher than its 52-week low of $3.25.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TherapeuticsMD’s stock is considered to be oversold (<=20).
Sales Growth
TherapeuticsMD’s sales growth is negative 91.2% for the ongoing quarter and negative 93.7% for the next.
More news about TherapeuticsMD (TXMD).
